CJC-1295 (with DAC)

A long-acting GHRH analogue bearing an albumin-binding linker, extending half-life from minutes to days. Reached early human trials; development discontinued. Prohibited in sport.

In human clinical trialsView CJC-1295 (DAC) in catalog →
Total citations4
Human clinical studies2
Animal models1
In vitro studies1
Reviews / meta-analyses0

Mechanism of action

CJC-1295 is a tetra-substituted analogue of human GHRH(1-29) carrying a maleimidopropionyl group at Lys30. That group forms a covalent bond with circulating albumin, extending the estimated half-life to 5.8–8.1 days in humans against minutes for native GHRH.

It acts as a GHRH-receptor agonist on pituitary somatotrophs, stimulating GH synthesis and release. Notably, Ionescu and Frohman showed that despite effectively continuous receptor stimulation, GH secretion remains pulsatile — the drug amplifies pulse amplitude rather than abolishing pulsatility.

Peer-reviewed literature

Study type is tagged on every entry so animal and in-vitro findings are never mistaken for human clinical evidence.

Human clinical

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Teichman SL, et al. · Journal of Clinical Endocrinology & Metabolism · 2006

Randomised placebo-controlled trials in healthy adults showing sustained elevation of GH and IGF-1 after single doses.

Human clinical

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

Ionescu M, Frohman LA · Journal of Clinical Endocrinology & Metabolism · 2006

Demonstrated that GH pulsatility is preserved under continuous GHRH-receptor stimulation, with increased pulse amplitude.

Animal model

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

Alba M, et al. · American Journal of Physiology — Endocrinology and Metabolism · 2006

Restored normal growth in GHRH knockout mice, supporting receptor-mediated activity in vivo.

In vitro

A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS

Timms M, et al. · Drug Testing and Analysis · 2019

Analytical method development for doping control, reflecting the compound’s prohibited status in sport.

Limitations & open questions

Material marketed as "CJC-1295 no-DAC" or "mod GRF 1-29" is a different compound without the albumin-binding linker, and does not share the extended half-life described here. The literature below concerns the DAC-bearing molecule (CAS 446262-90-4).

Research use only. All products listed on this site are sold strictly as laboratory reagents for in-vitro research and analytical use. They are not drugs, foods, cosmetics or medical devices, and are not intended to diagnose, treat, cure or prevent any disease. They are not for human or veterinary consumption or administration. Purchasers must be qualified researchers or institutions and are solely responsible for compliance with all applicable laws.